Back to overview

Hippo/YAP pathway for targeted therapy.

Type of publication Peer-reviewed
Publikationsform Review article (peer-reviewed)
Author Felley-Bosco Emanuela, Stahel Rolf,
Project From asbestos-exposure to cancer: a systemic approach to detect loss of homeostatic control in the mesothelial environment
Show all

Review article (peer-reviewed)

Journal Translational lung cancer research
Volume (Issue) 3(2)
Page(s) 75 - 83
Title of proceedings Translational lung cancer research
DOI 10.3978/j.issn.2218-6751.2014.02.03

Open Access

Type of Open Access Repository (Green Open Access)


Malignant pleural mesothelioma (MPM) is molecularly characterized by loss of function or mutations in the neurofibromin 2 (NF2) and the cyclin-dependent kinase inhibitor 2 genes. NF2 activates a cascade of kinases, called Hippo pathway, which downregulates Yes associated protein (YAP) function as transcription co-activator for TEA domain transcription factors (TEAD). In the absence of functional NF2, the expression of genes essential for cell cycling such as survivin is increased. New therapeutic strategies aimed at interfering with YAP activity include inhibition of hedgehog pathway, which downregulates the YAP protein, verteporfin, which inhibits the assembly of a functional YAP-TEAD transcription factor, and interference with thrombin and lysophosphatidic acid (LPA) receptors downstream signalling, since upon agonist binding they activate YAP.